Gutenberg Open Science: The status of adjuvant and neoadjuvant melanoma therapy, new developments and upcoming challenges

Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7641

Full metadata record

DC Field	Value	Language
dc.contributor.author	Stege, Henner	-
dc.contributor.author	Haist, Maximilian	-
dc.contributor.author	Nikfarjam, Ulrike	-
dc.contributor.author	Schultheis, Michael	-
dc.contributor.author	Heinz, Jaqueline	-
dc.contributor.author	Pemler, Saskia	-
dc.contributor.author	Loquai, Carmen	-
dc.contributor.author	Grabbe, Stephan	-
dc.date.accessioned	2022-08-30T09:27:46Z	-
dc.date.available	2022-08-30T09:27:46Z	-
dc.date.issued	2021	-
dc.identifier.uri	https://openscience.ub.uni-mainz.de/handle/20.500.12030/7655	-
dc.description.abstract	The global incidence of malignant melanoma, the leading cause of skin cancer death, has steadily increased in recent years. Surgical excision is the treatment of choice for early-stage melanoma. However, 40–60% of patients with high-risk melanoma or with nodal involvement eventually experience loco-regional relapse or tumor progression. Adjuvant therapy aims to reduce the rate of recurrence in radically operated high-risk patients with melanoma and thus improves survival. Interferon-α has long been the only approved drug for adjuvant melanoma therapy, despite an unclear survival benefit. The landmark success of immune-checkpoint inhibitors and BRAF/MEK-directed targeted therapies in the treatment of patients with stage IV melanoma led to the initiation of clinical trials in the adjuvant setting. These trials demonstrated the efficacy of immune-checkpoint inhibitors and targeted therapies for the adjuvant treatment of high-risk patients with melanoma, as shown both by an increase in recurrence-free survival and the emergence of long-term survivors, finally resulting in the approval of the cytotoxic T-lymphocyte antigen 4 inhibitor ipilimumab, PD1 inhibitors (nivolumab, pembrolizumab), and BRAF/MEK inhibitors for adjuvant melanoma therapy. This review aims to delineate the advances in adjuvant melanoma therapy, issuing particularly recent results from clinical trials. Moreover, we also discuss pending issues and future challenges, which comprise the adequate selection of adjuvant regimens for patient subgroups and the identification of markers likely to predict the individual response to adjuvant treatments. Last, we outline the role of emerging neoadjuvant approaches, which may complement adjuvant strategies and are currently investigated in clinical trials.	en_GB
dc.language.iso	eng	de
dc.rights	CC BY-NC	*
dc.rights.uri	https://creativecommons.org/licenses/by-nc/4.0/	*
dc.subject.ddc	610 Medizin	de_DE
dc.subject.ddc	610 Medical sciences	en_GB
dc.title	The status of adjuvant and neoadjuvant melanoma therapy, new developments and upcoming challenges	en_GB
dc.type	Zeitschriftenaufsatz	de
dc.identifier.doi	http://doi.org/10.25358/openscience-7641	-
jgu.type.dinitype	article	en_GB
jgu.type.version	Published version	de
jgu.type.resource	Text	de
jgu.organisation.department	FB 04 Medizin	de
jgu.organisation.number	2700	-
jgu.organisation.name	Johannes Gutenberg-Universität Mainz	-
jgu.rights.accessrights	openAccess	-
jgu.journal.title	Targeted oncology	de
jgu.journal.volume	16	de
jgu.pages.start	537	de
jgu.pages.end	552	de
jgu.publisher.year	2021	-
jgu.publisher.name	Springer Verlag France S.A.R.L.	de
jgu.publisher.place	Paris	de
jgu.publisher.issn	1776-260X	de
jgu.organisation.place	Mainz	-
jgu.subject.ddccode	610	de
jgu.publisher.doi	10.1007/s11523-021-00840-3	de
jgu.organisation.ror	https://ror.org/023b0x485	-
Appears in collections:	JGU-Publikationen

Files in This Item:

	File	Description	Size	Format
	the_status_of_adjuvant_and_ne-20220829114022401.pdf		1.17 MB	Adobe PDF	View/Open

Show simple item record